APN401
invIOs
[]
 the study also confirmed the feasibility of integrating our proprietary #celltherapy platform into daily clinical practice, enabling out-patient treatment and short treatment times. #aacr23 #apn401 #invios
Innovative immuno-oncology means developing tomorrow's cancer therapies, today.